Keyphrases
Israeli
100%
Antiphospholipid Syndrome
100%
Rituximab
100%
Antiphospholipid Antibodies
36%
Rituximab Therapy
27%
Complete Response
27%
B Cells
18%
No Response
18%
Antibody Titre
18%
Partial Response
18%
Israel
9%
Medical Records
9%
Medical Center
9%
Treatment Protocol
9%
Clinical Manifestations
9%
Response to Treatment
9%
Difficult-to-treat
9%
Antibody Status
9%
Retrospective Case Series
9%
Neurological Manifestations
9%
Antibody Response
9%
Therapeutic Response
9%
Potential Therapy
9%
Stent Thrombosis
9%
Clinical Indications
9%
Fixed-dose Combination
9%
Cytopenia
9%
Concomitant Medications
9%
Diffuse Alveolar Hemorrhage
9%
Skin Manifestations
9%
B-cell Depletion
9%
Medicine and Dentistry
Antiphospholipid Syndrome
100%
Rituximab
100%
Antiphospholipid Antibody
33%
B Cell
25%
Medical Record
8%
Thrombosis
8%
Treatment Response
8%
Pulmonary Hemorrhage
8%
Skin Manifestation
8%
Cytopenia
8%
Pharmacology, Toxicology and Pharmaceutical Science
Antiphospholipid Syndrome
100%
Rituximab
100%
Antiphospholipid Antibody
33%
Thrombosis
8%
Lung Hemorrhage
8%
Skin Manifestation
8%
Cytopenia
8%
Neuroscience
Antiphospholipid Syndrome
100%
Rituximab
100%
Phospholipid Antibody
33%
B Cell
25%